• Explore /
  • Poster
  • / Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.

Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.

Abstract Poster

Authors

Arsen Osipov

Arsen Osipov

Johns Hopkins University School of Medicine, Department of Oncology, Balimore, MD

Arsen Osipov , Aleksandra Popovic , Alexander Hopkins , Garrett M. Frampton , Lee A. Albacker , Nilofer Saba Azad , Daniel A. Laheru , Lei Zheng , Elizabeth M. Jaffee , Mark Yarchoan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Citation

J Clin Oncol 37, 2019 (suppl; abstr 2578)

DOI

10.1200/JCO.2019.37.15_suppl.2578

Abstract #

2578

Poster Bd #

222

Abstract Disclosures

Similar Posters

First Author: Olga Zamulko

First Author: Alessandra Anna Anna Prete

First Author: Mark N. Stein

First Author: Kimberly Loo